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Abstract
Background: Initial classification of diabetes of young may require revision to improve diagnostic accuracy of
different forms of diabetes.
The aim of our study was to examine markers of beta-cell autoimmunity in a cohort of young (0–25 years) patients
with type 1 diabetes and compare the presentation and course of the disease according to the presence of
pancreatic antibodies.
Methods: Cross-sectional population-based study was performed covering 100% of pediatric (n = 860) and 70% of
18–25 years old adult patients (n = 349) with type 1 diabetes in Lithuania.
Results: No antibodies (GAD65, IA-2, IAA and ICA) were found in 87 (7.5%) cases. Familial history of diabetes was
more frequent in those with antibodies-negative diabetes (24.1 vs. 9.4%, p < 0.001). Gestational age, birth weight
and age at diagnosis was similar in both groups. Ketosis at presentation was more frequent in patients with
autoimmune diabetes (88.1 vs. 73.5%, p < 0.05). HbA1c at the moment of investigation was 8.6 (3) vs. 8.7 (2.2)% in
antibodies-negative and antibodies-positive diabetes groups, respectively, p > 0.05. In the whole cohort, neuropathy
was found in 8.8% and nephropathy - in 8.1% of cases, not depending on autoimmunity status. Adjusted for age at
onset, disease duration and HbA1c, retinopathy was more frequent in antibodies-negative subjects (13.8 vs. 7.8%, p
< 0.05).
Conclusion: Antibodies-negative pediatric and young adult patients with type 1 diabetes in this study had higher
incidence of family history of diabetes, higher frequency of retinopathy, less frequent ketosis at presentation, but
similar age at onset, HbA1c, incidence of nephropathy and neuropathy compared to antibodies-positive patients.
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Background
Diabetes at young age is predominantly type 1 diabetes - a
chronic autoimmune disease, caused by an interplay of gen-
etic susceptibility and environmental factors [1, 2]. The in-
cidence of type 1 diabetes is rising worldwide, particularly
in young children [1, 3, 4], and varies from the lowest
values reported in China and Venezuela (0.1 per 100,000
inhabitants per year) to the highest recorded in Finland
(42.9 per 100,000 inhabitants per year) [2–4]. DIAMOND
project results showed the average 2.8% of annual increase
in incidence of type 1 diabetes calculated from data of 103
centers [5]. The standard incidence of type 1 diabetes in
Lithuania is 10.42 (95℅ - CI 10.01–10.85) per 100,000 per-
sons aged 0–14 years and the average of annual incidence
increase by 4.75℅ (Urbonaite B, unpublished data).
The risk for developing type 1 diabetes increases with
genetic susceptibility and the presence of immunological
markers of beta-cell autoimmunity. Antibodies may be
used as markers of beta-cell destruction and reflect dis-
ease severity [6, 7]. Type 1 diabetes is characterized by the
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presence of antibodies to a 65 kD glutamic acid decarb-
oxylase antigen (GAD65), antibodies against protein tyro-
sine phosphatase (IA-2), insulin antibodies (IAAs), islet
cell antibodies (ICAs) and zinc transporter 8 (ZnT8A) in
blood that identify the autoimmune process leading to
beta-cell destruction [8]. A recent experience shows that
the initial classification of diabetes of young requires revi-
sion in about 10% of cases in whom monogenic forms of
diabetes might imply different treatment modalities [9].
Therefore, an in depth characterization of young patients
with diabetes, including the analysis of pancreatic auto-
immune antibodies is mandatory to improve diagnostic
accuracy of the different forms of diabetes.
The aim of our study was to examine markers of beta-
cell autoimmunity in a cohort of young (0-25 years of age)
patients with type 1 diabetes and compare the presentation
and course of the disease according the presence of
immunological markers.
Methods
Study design and subjects
A cross sectional population-based study was conducted
in a single research center as a part of joint Lithuanian–
Swiss project “Genetic Diabetes in Lithuania”. The prin-
cipal aim of this project is to screen all patients with
type 1 diabetes under the age of 25 years in Lithuania
for autoimmune antibodies in order to select patients
for genetic testing for monogenic diabetes and to com-
pare clinical presentation of antibodies-positive and
antibodies-negative subjects.
Our cohort consisted of 1209 subjects covering all
pediatric patients (<18 years, n = 860), and part of adult
patients younger than 25 years (n = 349) diagnosed with
type 1 diabetes. All patients had a physician diagnosis of
type 1 diabetes between March 1990 and March 2015.
According to the national Lithuanian type 1 diabetes
registry, the study cohort covered 100% of all pediatric
and 70% of 18–25 years old adult patients with type 1
diabetes in Lithuania.
Patients with diagnosed type 1 diabetes (up to 25 years
of age, regardless of the duration of the disease) were
identified from Lithuanian national type 1 diabetes data-
base and invited to participate in the study on their visit
to the family doctor and/or endocrinologist, a pediatric
endocrinologist, meetings of diabetes societies, as well as
by post, e-mails and phone calls. Patients were recruited
and enrolled into the study between January 2013 and
April 2015. 164 patients were newly diagnosed with type
1 diabetes at study entry, and in 1045 subjects diabetes
duration was from 2 weeks to 24.7 years.
At the study entry, data on age at onset of diabetes, dia-
betes duration, gestational age and birth weight, the daily
insulin dose, presentation of the disease and family history
of diabetes were collected. Clinical examination included
height (cm), weight (kg), arterial blood pressure, heart
rate, examination of feet and eye fundus. The data on ges-
tational age and birth weight were selected from medical
documentation when available and from questionnaire.
At study entry, all study subjects were investigated for
pancreatic autoimmune markers (GAD65, IA-2, IAAs,
ICAs) and coexistence of other autoimmune diseases
(thyroid, celiac disease). Diabetes control was assessed
by levels of HbA1c. Fasting blood samples were taken
for analysis of lipid profile. Patients were all screened for
diabetes complications: retinopathy, nephropathy and
neuropathy.
Laboratory analyses
Glycosylated hemoglobin (HbA1c), lipids, serum creatin-
ine were measured by UniCel DxC 800 Synchron system
(Beckman Coulter, USA). The normal cut-off values of
HbA1c were 4–6% (20 mmol/mol – 42 mmol/mol). Op-
timal metabolic control was defined by HbA1c <7.5%
(58 mmol/mol) for children [10] and adults [11]. Dyslip-
idemia was defined as LDL-cholesterol ≥2.59 mmol/l,
HDL-cholesterol ≤1.55 mmol/l, total cholesterol ≥5.2
mmol/l for patients ≥16 years and ≥5.5 for children
under 16 years, and triglycerides ≥1.95 mmol/l. Dyslipid-
emia was considered present if one or more of these
lipid or lipoprotein levels were abnormal.
Ketosis at diagnosis was defined as presence of keto-
nuria (urine ketone body 1+ and above) or diabetic
ketoacidosis [10].
Thyroid antibodies (ATPO) and thyroid hormones (TSH, FT4)
ATPO (normal range, 0–78 U/ml), TSH (normal range
0.27–3.5 mU/ml) and FT4 (normal range 10–22 pmol/l)
were measured using open analyzer system on a radio-
active basis for radioimmunoassays SR300 (Stratec Bio-
medical Systems AG (Germany)).
Thyroid function was evaluated as hypothyroidism,
subclinical hypothyroidism, hyperthyroidism and sub-
clinical hyperthyroidism. Subclinical hypothyroidism was
diagnosed when FT4 levels were within normal reference
laboratory range but TSH levels were elevated. Subclin-
ical hyperthyroidism was defined as TSH level below
0.27 mU/ml and FT4 within normal range.
Tissue transglutaminase IgA antibodies (tTG-A) were
measured by enzyme immunoassay (ELISA) kits, using
Gemini analyzer (Stratec Biomedical Systems AG
(Germany)). Concentrations >18 U/ml for tTG-A were
considered positive, - between 12 and 18 U/ml – border-
line and concentrations <12 U/ml - normal.
Pancreatic antibodies
GAD65, IA-2, IAAs antibodies were measured by radio-
immunoassay (RIA) using γ-ray counter BERTHOLD
(Germany), and ICAs antibodies were measured by
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enzyme immunoassay (ELISA) and evaluated by means
of microtiter plate reader STAT FAX2100 (USA).
DEMEDITEC’s Diagnostics GmbH (Germany) assay kits
were used, as previously described [12–14].
GAD65 antibodies measuring range was 1–300 U/ml.
The lowest detection limit at +2SD was 0.11 U/ml. As-
say’s negative cut-off was ≤1.0 U/ml, and positive >1.0
U/ml. Inter-assay coefficient of variation (CV) was 6.9%,
intra-assay CV-3.7%, specificity and sensitivity were 95%
and 84%, respectively.
IA-2 antibodies RIA assay measuring range was 1–50 U/
ml. The lowest detection limit at +2 SD was 0.16 U/ml. As-
say’s negative cut-off was ≤1.0 U/ml and positive - > 1.0 U/
ml. Inter-assay CV was 5.3%, intra-assay CV - 2.8%, specifi-
city and sensitivity were 100% and 70%, respectively.
IAAs antibodies measuring range was 0.4–50 U/ml. The
lowest detection limit at +2 SD was 0.03 U/ml. Assay’s
negative cut-off was < 0.4 U/ml, and positive - ≥0.4 U/ml.
Inter-assay CV was 8.0%, and intra-assay CV - 3.3%.
ICAs antibodies assay is qualitative ELISA test for in
vitro detection of circulating IgG antibodies against islet
cell antigens in human serum [14]. Samples with optical
density ratio values ≤0.95 show a low level of ICAs anti-
bodies (negative result), values >0.95 show a high level
(positive result).
Evaluation of microvascular diabetes complications
Retinopathy
Retina examination was performed by a single diabetes
ophthalmologist. The digital fundus photographies were
used for the evaluation of diabetic eye disease.
Albumin excretion rate (AER)
24 hour urine albumin excretion rate (AER) was calculated
as described previously [15] and defined as normal when
AER < 30mg/24h; microalbuminuria–when AER 30-300
mg/24h, macroalbuminuria–when AER > 300 mg/24h.
Neuropathy
Clinical neuropathy was defined as the presence of
symptoms and signs consistent with distal symmetrical
peripheral neuropathy. Michigan Neuropathy Screening
Questionnaire was applied and vibration sensation was
tested in the great toe using a 128-Hz tuning fork, pres-
sure sensation test with Semmes-Weinstein 10g mono-
filament and temperature sensation test with thermal
sensitivity tester Tip Therm were used for neuropathy
screening. Peripheral neuropathy was diagnosed when
two or more of the tests were abnormal [16, 17].
Statistical analyses
Statistical analyses were performed using SPSS software
version 20.0. The data were evaluated using Student’s 2-
tailed t test, χ2 statistics, parametric one way ANOVA
(in the case of normal distribution) and Mann–Whitney
U-test (in the case of non-normal distribution) or Krus-
kall Wallis one-way ANOVA (in the case of ordinal
data). P values <0.05 were assigned statistical signifi-
cance. All P values are 2-tailed.
Results
General characteristics of the cohort
The mean age at the onset of diabetes was 9.9 (5.3) years
(0.01–24.8 years, median 9.7 years). In 4 cases the age at
onset of diabetes was less than 6 months, corresponding
to neonatal diabetes form, confirmed later with genetic
testing and identification of mutation in KCNJ11 gene.
The peaks of onset of diabetes occurred in two age
groups: 5–9 years and 10–14 years (Fig. 1). The mean
age of patients was 15 (6.2) years. The mean duration of
diabetes was 5.1 (5) years (0.01–24.7, median 3.8 years).
No gender predominance was apparent in our cohort
(males 48.5%).
Autoimmunity status
No immunological markers of beta-cell autoimmunity
were found in 87 cases (7.5%) (Table 1) of the whole co-
hort, and in 20 cases (12.2%) among newly diagnosed
diabetic patients (Table 3). Four patients with neonatal
diabetes (onset before 6 months of age) were on insulin
treatment at the time of investigation; in 3 cases no anti-
bodies were found, and IAAs were present in one case.
All negative immunological markers were found more
frequently in the youngest (0–4 years) and the oldest
(20–24 years) patients groups, and with the duration of
diabetes ≥14 years (Fig. 2). Positive ICAs were observed
least frequently in the whole cohort (Table 2) and in
newly diagnosed diabetic patients (Table 3).
Positive IA-2 antibodies were found in two thirds of
patients with the age at onset of diabetes 5–19 years,
whereas higher frequency of GAD65 antibodies was ob-
served in older ones and was found in two thirds with
age at onset 15–24 years (Fig. 3). The frequency of both
positive GAD65 and IA-2 was higher in patients with
longer duration of the disease (Fig. 4).
Birth data and family history of diabetes
The mean gestational age in our cohort was 39.4 (1.6)
weeks, 4.1% were born preterm (<37 gestational weeks).
0.1% of subjects were born of very low birth weight
(<1500 g) and 2.2% were born of low birth weight
(<2500 g). There were no differences neither in birth
data nor gender distribution according to autoimmunity
status (Table 2).
Almost one third (31.9%) of patients had positive family
history of diabetes among first, second or third-degree rel-
atives. The first degree relatives had diabetes in 10.8% of
study cases, significantly more frequently in antibodies-
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negative subjects (Table 2). Second degree relatives with
diabetes were reported in 26.2%, and third degree rela-
tives- in 16.4% of cases. 8 (0.7%) patients had very strong
positive family history among first, second and third-
degree relatives.
Disease presentation
Age at onset of diabetes was similar in antibodies-negative
and antibodies-positive (with at least one positive anti-
body) patients. However, patients with 3 and more posi-
tive antibodies were significantly younger at disease onset
compared to antibodies-negative subjects (Table 2).
Ketosis at the time of diagnosis was present in 542
(87.3%) of 621 cases in whom data were available. Ketosis
was significantly more frequent in patients with no family
history of diabetes (91.2% vs. 78.3%, p < 0.05) and in the
antibodies-negative group (88.1 vs. 73.5%, p < 0.05). In the
subcohort with newly diagnosed diabetes, ketosis was also
more frequent among those with all negative autoimmunity
markers than with at least one positive antibody (Table 3).
Diabetes management and control
In the whole cohort, mean HbA1c at the study entry was
8.7 (2.3)% (72 (2) mmol/mol) (4.7–19.9% (28–194 mmol/
mol), median 8.3% (67 mmol/mol)). The highest HbA1c
was observed in adolescents and young adults groups
(Fig. 5), although neither age group had optimal glycemic
control. Males had slightly but significantly better glycemic
control than females (8.5 (2.1)% (69 (1) mmol/mol) vs. 9
a
b
Fig. 1 The distribution of patients by age at the onset of diabetes (a) and diabetes duration (b) groups
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(2.3)% (74 (2) mmol/mol), p < 0.05). HbA1c was similar be-
tween patients in antibodies-negative and antibodies-
positive subjects; however, comparisons of patients with dif-
ferent antibodies types to antibodies-negative ones revealed
significantly higher HbA1c in those positive for only
GAD65 antibodies (Table 2).
The mean daily insulin dose in the whole cohort
was 0.79 (0.35) U/kg/d. The mean insulin dose in
antibodies-negative patients was significantly lower
than in patients with at least one positive antibody in
the whole cohort (0.63 (0.4) vs. 0.77 (0.4), p = 0.001,
respectively) (Table 2), and also in the subcohort with
newly diagnosed T1D patients (0.43 (0.3) vs. 0.71
(0.4), p = 0.002, respectively) (Table 3).
Microvascular complications and dyslipidemia
Neuropathy was present in 100 (8.8%) and retinopathy
- in 96 (8.2%) of our patients. There was one case of
diabetic cataract in a 14 years old adolescent. Elevated
AER was found in 94 (8.1%) cases. Adjusted for age at
onset, disease duration and HbA1c, antibodies-
negative patients had significantly higher incidence of
retinopathy, compared with antibodies-positive sub-
jects, and similar incidence of neuropathy and ne-
phropathy, although the latter was almost two times
less frequent in antibodies-negative group, but the dif-
ference did not reach significance, possibly due to
small numbers of patients with nephropathy in the
antibodies-negative group (Table 2). We found signifi-
cant relationships between age, duration of diabetes,
glycemic control, insulin dose and all microvascular
complications. Detailed comparison of patients with
and without microvascular complications is shown in
Table 4.
84.9% (n = 990) of the cohort had abnormal lipid pro-
file. Patients with dyslipidemia had higher HbA1c ((8.8
(2.3)% vs. 8.1 (1.8)%, p < 0.05), but also longer duration
of DM (5.2 (5) vs. 5 (4.9) yrs; p = 0.572). Presence of
pancreatic antibodies was not related to the incidence of
dyslipidemia (Table 2).
Co-existing autoimmune conditions
Thyroid antibodies (ATPO-Abs) were found in 13.8% of
the entire cohort, significantly more frequently among
patients with at least one positive pancreatic antibody
(14.6% vs. 3.1%, respectively). Thyroid dysfunction was
detected in 18.8% of cases: hypothyroidism was evident
in 0.63%, subclinical hypothyroidism – in 16.9%, subclin-
ical hyperthyroidism – in 1.26% of cases. Thyroid dys-
function was significantly more prevalent in females (p
= 0.014).
Positive tTG-A were detected in 3.7% of patients, only
in antibodies-positive subjects. Highest frequency of
positive tTG-A was found in the youngest age at diagno-
sis group (7.4% in 0–4 years of age at diabetes onset
group).
Discussion
The main strength of this study is the clinical and im-
munological characterization of a national cohort of all
children and the majority of young adults up to 25 years
of age with type 1 diabetes.
Epidemiological data on childhood diabetes (0–14
years) in Lithuania are registered since 1983 [18, 19]. Ac-
cording to national registry, average annual type 1 dia-
betes incidence increase is 4.75%, and that of prevalence
- 6.5%; therefore, the population of young people with
diabetes constantly increases [20]. Traditionally, the
diagnosis of diabetes is based on clinical data only, the
age at onset of hyperglycemia without obesity being the
main diagnostic criteria.
The appearance of autoantibodies to one or several of
the autoantigens -GAD65, IA-2, IAAs, ICA or ZnT8 sig-
nals an autoimmune pathogenesis of β-cell destruction
and indicates condition‘s severity, the presence of multiple
autoantibodies having the highest positive predictive value
for type 1 diabetes [6, 21, 22].
The presence of GAD65 in type 1 diabetes was shown
to depend on age at diagnosis and gender: GAD65
Table 1 Frequency of various antibody combinations in
patients with diabetes
Number Frequency (%)
No detectable antibodies 87 7.5
Single Ab +
GAD65 + 38 3.3
IA-2 + 50 4.3
IAAs + 178 15.3
ICAs + 8 0.7
Two Ab’s +
GAD65 + and IA-2 + 415 35.6
GAD65 + and IAAs + 458 39.3
GAD65 + and ICAs + 38 3.3
IA-2 + and IAAs + 505 43.3
IA-2 + and ICAs + 42 3.6
IAAs + and ICAs + 64 5.5
Three Ab’s +
GAD65 +, IA-2 +, IAAs + 298 25.6
GAD65 +, IA-2 +, ICAs + 25 2.1
GAD65 +, IAAs +, ICAs + 31 2.7
IA-2 +, IAAs+, ICAs + 34 2.9
All four Ab’s + 30 2.6
Ab antibody, GAD65 antibodies against glutamic acid decarboxylase antigen
65 kD, IA-2 antibodies against protein tyrosine phosphatase, IAAs insulin
antibodies, ICAs islet cell antibodies
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Fig. 2 The frequency of antibodies-negative diabetes in age at investigation (a), age at the onset of diabetes (b) and diabetes duration groups (c)
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Table 2 Comparison of clinical features between groups of DM patients according to autoimmunity status
No Ab’s
(n = 87; 7.5%)
≥1 Ab +
(n = 1079; 92.5%)
Only GAD65 +
(n = 38; 3.3%)
Only IA-2 +
(n = 50; 4.3%)
Only ICAs +
(n = 8; 0.7%)
Only IAAs +
(n = 178; 15.3%)
2 Ab’s +
(n = 477; 40.9%)
3 Ab’s +
(n = 308; 26.4%)
Age (yrs) 15.87 15 (6) 16.5 (7) 14 (7.3) 17.8 (4.4) 15.7 (5.7) 14.9 (6.1) 15 (5.9)
Age at onset of DM (yrs) 10.6 (6.3) 9.8 (5.2) 12 (6.9) 9.3 (5.5) 10.9 (4.4) 7.9 (5.7) 9.8 (5.2) 9.6 (5.4)
Duration of DM (yrs) 5.3 (6.3) 5.1 (4.8) 4.4 (6) 4.7 (5.8) 5.9 (4.9) 5.4 (5) 5.2 (4.9) 5.4 (5)
Birth weight (gr) 3473 (568) 3515 (502) 3389 (389) 3619 (497) 3638 (680) 3492 (507) 3492 (507) 3501 (488)
Gestational age (weeks) 39.6 (1.2) 39.4 (1.6) 39.4 (1.2) 39.3 (2) 39.5 (1.2) 39.6 (1.2) 39.5 (1.4) 39.4 (1.6)
Males (%) 48.3 48.5 39.5 58 75 46.6 48.4 51
Positive family history of diabetes
(1st degree relatives) (%)
24.1 9.4b 2.6c 6d 37.5 10.1 10.5 11
HbA1c (%) 8.6 (3) 8.7 (2.2) 10 (2.5)e 9.5 (2.1) 7.9 (2.3) 8.6 (1.9) 8.6 (2.1) 8.6 (2.1)
Insulin dose (U/kg/d) 0.63 (0.4) 0.77 (0.4)f 0.81 (0.4)g 0.74 (0.3)h 0.81(0.4) 0.79 (0.4)i 0.76 (0.4) 0.74 (0.4)
Positive ATPO (%) 3.1 14.6j 11. 6.7 16. 11.6 13.6 15.7
Positive tTG-A (%) 0 3.9 9.1 2.6 0 3.9 2.9 3.9
Dyslipidemia (%) 83.9 85.7 89.5 90 87.5 86 83.6 85.7


















Retinopathy 13.8% (n = 12) 7.8% (n = 84)p 7.9% (n = 3) 12% (n = 6) 25% (n = 2) 9.1% (n = 28) 8.4% (n = 40) 9.1% (n = 28)
Neuropathy 10.8% (n = 9) 8.7% (n = 91) 5.7% (n = 2) 14% (n = 7) 0 8.6% (n = 26) 10.2% (n = 47) 8.6% (n = 26)
Nephropathy (AER > 300 mg) 4.8% (n = 4) 8.8% (n = 91) 7.9% (n = 3) 2% (n = 1) 12.5% (n = 1) 9.2% (n = 27) 8% (n = 37) 9.2% (n = 27)
All parameters are presented as mean (±SD) values unless otherwise stated
Ab antibody, GAD65 antibodies against glutamic acid decarboxylase antigen 65 kD, IA-2 antibodies against protein tyrosine phosphatase, IAAs insulin antibodies, ICAs islet cell antibodies, DM diabetes mellitus, yrs years,
gr grams, HbA1c glycosylated hemoglobin, ATPO thyroid peroxidase antibodies, tTG-A tissue transglutaminase antibodies, AER albumin excretion rate
a - present ketosis out of whom data was available













Table 3 Comparison of clinical features between groups of newly diagnosed DM patients (n = 164) according to autoimmunity status
No Ab’s
(n = 20; 12.2%)
≥1 Ab +
(n = 144; 87.8%)
Only GAD65 +
(n = 11; 6.7%)
Only IA-2 +
(n = 19; 11.6%)
Only ICAs +
(n = 2; 1.2%)
Only IAAs +
(n = 3; 1.8%)
2 Ab’s +
(n = 78; 47.6%)
3 Ab’s +
(n = 28; 17.1%)
Age at onset of DM (yrs) 15.8 (6.5) 11.5 (6.1) b 16.1 (7.3) 9.8 (6) f 14.7 (1.2) 10.9 (8.7) 12.1 (5.5) h 8.5 (5.8)k
Birth weight (gr) 3643 (699) 3470 (485) 3312 (421) 3628 (443) 3200 2920 (1018) 3477 (502) 3475 (408)
Gestational age (weeks) 39.4 (1) 39.6 (1.5) 39.2 (1.8) 39.6 (1.3) 40 40 39.6 (1.7) 39.7 (1)
Males (%) 45 45.1 18.2 57.9 50 33.3 46.2 50
Positive family history of diabetes
(1st degree relatives) (%)
10 11.1 9.1 10.5 50 33.3 10.3 10.7
HbA1c (%) 9.9 (3.7) 10.9 (2.3) 11.5 (2.2) 10.8 (1.5) 6.2 (0.1) 7.7 (1.4) 11.3 (2.3)i 10.3 (2.3)
Insulin dose (U/kg/d) 0.43 (0.3) 0.71 (0.4) c 0.8 (0.4) e 0.77 (0.3) g 0 0.39 (0.3) 0.75 (0.4) j 0.62 (0.4)
Positive ATPO (%) 5.9 14.2 28.6 0 0 0 18.3 8.3
Positive tTG-A (%) 0 7.4 20 6.3 100 – 8.2 5
Dyslipidemia (%) 80 86.8 81.8 94.7 100 100 84.6 85.7














All parameters are presented as mean (±SD) values unless otherwise stated
Ab antibody, GAD65 antibodies against glutamic acid decarboxylase antigen 65 kD, IA-2 antibodies against protein tyrosine phosphatase, IAAs insulin antibodies, ICAs islet cell antibodies, DM diabetes mellitus, yrs years,
gr grams, HbA1c glycosylated hemoglobin, ATPO thyroid peroxidase antibodies, tTG-A tissue transglutaminase antibodies
a - present ketosis out of whom data was available













positive female diabetic patients have higher GAD65
levels and a more severe loss of β-cell function than
male patients with the same age at diagnosis [23].
GAD65 is less frequent among boys developing diabetes
before the age of 10 years, with diagnostic sensitivity
over 80% in both males and females in older children,
teenagers, and young adults [22]. In our cohort, highest
frequency of positive GAD65 antibodies was in patients
with disease onset between 14 and 19 years (66.4%).
We have found positive GAD65 antibodies in 52.7%, IA-
2 in 57.8%, IAAs in 73.9%, and ICAs in 7% of cases; 36.5%
of patients had both GAD65 and IA-2 antibodies. Pardini
et al have reported positive GAD65 in 80.0%, IA-2 - in
62.9% and both GAD65 and IA-2 - in 82.9% of cases with
recent-onset type 1 diabetes. The frequency of positive
antibodies was lower in cases with long duration of type 1
diabetes [24],which is similar to our findings: all types of
antibodies had tendency to be lower in subjects with lon-
ger duration of diabetes, and highest proportion of all
negative antibodies was found in patients with longest
duration of type 1 diabetes.
It has previously been reported that frequency of
positive ICAs declines following diagnosis, and remains
positive in less than 5–10% of type 1 diabetes patients
after 10 years [25]. On the contrary, in our study fre-
quency of positive ICAs was surprisingly low in the 0–4
years disease duration group (5.4%), and much higher
in those with 15–19 years duration (11.1%). Several lon-
gitudinal studies indicate that type 1 diabetes patients
remain GAD65 and/or IA-2 positive up to 80% after 12
years [26, 27].
Ketosis at the time of diagnosis is a typical feature
of type 1 diabetes, and was present in 87.3% of cases
in our study. It was less frequent among youth with
family history of diabetes, which is probably due to
alertness of family members to initial signs and
symptoms of the disease. Also, ketosis was less fre-
quent finding at diagnosis in patients with non-
autoimmune diabetes, which might indicate a differ-
ent cause and mechanism of hyperglycemia, at least
in part of these patients group.
Most cases of type 1 diabetes occur sporadically in the
absence of family history of diabetes [28]. The empiric
risk of being affected if a first-degree relative has dia-
betes is 5% [29]. Although more than 85% of patients
with type 1 diabetes lack a positive family history, a high
familial clustering with a mean prevalence of 6% in sib-
lings is usually found [30]. In our study, the frequency of
first-degree relatives with either types of diabetes was
10.8% in the whole cohort, and was significantly higher
in patients with negative autoantibodies (24.1% vs. 9.4%,
p < 0.001), possibly indicating different pathways of dis-
ease inheritance.
Nonproliferative retinopathy was found in 8.2% of our
patients, and was observed in older patients with longer
duration of diabetes. Although the facilities for the man-
agement of diabetes are constantly improving, the risk of
retinopathy remains high. The Oulu cohort study reports
extremely high prevalence of diabetic retinopathy and pro-
liferative diabetic retinopathy (94% and 35%, respectively)
in patients who have had diabetes since childhood after 18
years of follow up [31]. Interestingly, we found signifi-
cantly higher frequency of all negative antibodies among
patients with retinopathy in our cohort, indicating a simi-
lar or even higher risk for development of this complica-
tion in antibodies-negative forms of diabetes. We also
found higher levels of IA-2 antibody and IAAs levels
among patients without retinopathy, this could be related
with higher residual β-cell function, as reported by other
authors, although they mainly analyzed inverse relation-
ship between GAD65 antibody levels and severe retinop-
athy in young type 1 diabetic patients [32].
Fig. 3 a Frequency of positive antibodies among age the onset of diabetes groups. b Frequency of positive antibodies according to diabetes duration
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Neuropathy was present in 8.8% of cases in our
study. Autoimmunity status was not different in pa-
tients with and without neuropathy. Similar frequency
of neuropathy (8.2%) was found in type 1 diabetes pa-
tients in SEARCH pilot study [33], although low re-
producibility of vibration perception threshold values
in young age was previously reported [34].
Elevated AER was found in 94 (8.1%) cases of our
young cohort, and was linked to older age at study
entry, longer disease duration, higher HbA1c and
higher daily insulin dose. Presence of pancreatic auto-
antibodies was again not related to elevation of AER,
indicating comparable risk of diabetic nephropathy in
both antibodies-positive and antibodies-negative dia-
betes, which seems to be more related to diabetes dur-
ation and control. A more intensive follow-up is
needed in these cases, since the data from Finnish
FinnDiane study showed that almost all of the excess
mortality seen in type 1 diabetes was related to the
development of micro- or macroalbuminuria [35].
Similar results were reported in The Pittsburgh Com-
plications Study [36]. On the other hand, frequency of
increased AER in our study was twice lower in the
antibodies-negative group, and possibly did not reach
statistical significance because of small number of pa-
tients with elevated AER in this group.
We must admit that the main weakness of our study
was measurement of pancreatic antibodies in both
newly diagnosed patients and in patients who were
already on insulin treatment, which was partly respon-
sible for high frequency of IAAs in our cohort. There-
fore, a proportion of subjects with positive only IAAs
might in fact have non-autoimmune form of diabetes,
as one patient with neonatal diabetes positive for IAA.
Fig. 4 Mean (± SD) HbA1c (%) according to: (a) age at investigation (p = 0.004 between age groups 5–9 and 15–19 years); (b) age at onset of
diabetes (p < 0.05 between age at onset 0.5–4 years group and 5–9, 10–14, 15–19 and ≥20 year groups; p = 0.036 between age at onset groups
5–9 and 10–14 years); (c) diabetes duration (p = 0.003 between groups 0–4 and 10–14 years; p = 0.024 between groups 5–9 and 10–14 years)
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Moreover, even in presence of autoimmune markers,
the likelihood of monogenic diabetes origin cannot be
excluded, as demonstrated in some studies [37]. On the
other hand, ZnT8 antibodies have not been determined
in our cohort, implying that some subjects with negative
antibodies might include individuals with undetected
autoimmunity. Furthermore, reduction in levels and even
disappearance of autoantibodies in the course of the dis-
ease is a well known phenomenon in diabetic patients,
making the subject even more complex.
Another study limitation is that according to na-
tional type 1 diabetes register the study population
covered 70% of young 18–25 years old adults, since at
this age many young individuals are moving abroad
or are busy in their work and therefore are not
available for investigations. Nevertheless, we screened
all pediatric and 70% of young adult population with
type 1 diabetes in Lithuania, identifying their auto-
immune status, metabolic control and diabetes com-
plications. This extensive characterization of the
cohort will allow us to proceed to genetic testing of
subjects with antibodies-negative diabetes for eventual
identification of monogenic forms, which might enable
an optimization of treatment and further follow-up of
such patients.
Conclusions
In summary, no immunological markers of beta-cell
autoimmunity were found in 7.5% of our cohort of
young T1D patients, and in 12.2% of newly diagnosed
diabetic patients. Antibodies-negative patients with pre-
sumed type 1 diabetes in this study had higher incidence
of family history of diabetes, higher frequency of retin-
opathy, less frequent ketosis at presentation, but similar
Fig. 5 Mean (± SE) HbA1c (%) according to the age at investigation (a), age at the onset of diabetes (b) and diabetes duration (c)
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age at onset, HbA1c, incidence of nephropathy and
neuropathy compared to antibodies-positive patients.
Further genetic testing in antibodies-negative patients
needs to be performed in order to elucidate the origin of
the disease. Nevertheless, optimal diabetes management
remains the most important way to prevent development
of microvascular complications and to achieve better
quality of life in all patients with diabetes.
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Table 4 Clinical characteristics and autoimmunity status according to presence of diabetic microvascular complications
Retinopathy Neuropathy AER No
microvascular
alterations
Present Absent Present Absent Elevated Normal
Age at the onset (yrs) 8.1 (4.3)b 10 (5.4) 9.9 (5)h 9.7 (5.2) 9.9 (5.1)n 9.8 (5.3) 9.9(5.4)
p = 0.001 p = 0.655 p = 0.821
Age at study entry (yrs) 20.7 (3.8)c 14.5 (6) 20.6 (4.2)i 14.2 (5.9) (4.2)o 14.2 (5.9) 14 (6)
p = 0.0001 p = 0.0001 p = 0.0001
Duration (yrs) 12.6 (4.8)d 4.5 (4.4) 10.7 (5)j 4.5 (4.5) 10.7 (5)p 4.5 (4.5) 4.1 (4.2)
p = 0.0001 p = 0.0001 p = 0.0001
HbA1c (%) 10 (2.3)e 8.6 (2.2) 9.3 (2.3)k 8.7 (2.2) 9.3 (2.3)q 8.7 (2.2) 8.5 (2.2)
p = 0.0001 p = 0.005 p = 0.001
Insulin dose (U/kg/d) 0.91 (0.3)f 0.78 (0.3) 0.86 (0.3)l 0.78 (0.3) 0.86 (0.3)r 0.78 (0.3) 0.74 (0.4)
p = 0.0001 p = 0.01 p = 0.044
All negative antibodies (%)a 12.5g 7 9m 7.2 9s 7.2 7.2
p = 0.046 p = 0.637 p = 0.456
GAD65 Ab levels (U/ml) 6.5 (18.6) 11.6 (28.9) 11.4 (29.5) 11.1 (28.2) 8.3 (18.9) 11.4 (28.9) 11.6 (29.3)
p = 0.092 p = 0.913 p = 0.307
IA-2 Ab levels (U/ml) 1.6 (3.3) t 5.8 (10.7) 2.5 (5.7)w 5.7 (10.6) 5.4 (13.8) 5.5 (10) 5.9 (10.4)
p = 0.0001 p = 0.003 p = 0.975
IAAs levels (U/ml) 7.2 (10.2) x 11.4 (15.3) 9 (15.7) 11.3 (14.9) 7.2 (11.1) y 11.4 (15.2) 11.8 (15.3)
p = 0.007 p = 0.145 p = 0.008
All parameters are presented as mean (±SD) values unless otherwise stated
yrs years, HbA1c glycosylated hemoglobin, AER albumin excretion rate, Ab antibody, GAD65 antibodies against glutamic acid decarboxylase antigen 65 kD, IA-2
antibodies against protein tyrosine phosphatase, IAAs insulin antibodies
a-comparisons between groups adjusted for age at the onset of diabetes, duration and HbA1c
P values comparing the group with microvascular complication with the groups without microvascular alterations: b 0.002, c 0.0001, d 0.0001, e 0.0001, f 0.001, g
0.066, h 0.889, i 0.0001, j 0.0001, k 0.001, l 0.005, m 0.527, n 0.886, o 0.0001, p 0.0001, q 0.0001, r 0.032, s 0.394, t 0.001, w 0.006, x 0.004, y 0.003
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